Research finds ECOG scores restrict patient access to trials, preventing trials from accurately representing real-world patients

HHS said it would terminate Women’s Health Initiative, then reconsidered

On April 21, Women’s Health Initiative investigators were informed that HHS would be terminating the WHI Regional Center contracts at the end of the current fiscal year.

April 25, 2025

Vol.51 No.16

By Jacquelyn Cobb and Claire Marie Porter

Cancer Policy

NIH notice prohibits grant awardees from operating programs that promote DEI

NIH, in a recent notice, prohibits grant recipients from operating programs that promote DEI or “discriminatory equity ideology,” or engage in “discriminatory prohibited boycott.”

Federal judges rule that Department of Education policy ordering universities to end DEI programs a violation of educators’ free speech

Federal judges in Maryland, New Hampshire and Washington, DC, blocked the Trump administration from following through on threats to cut off funding to universities that engage in DEI efforts.

Swim Across America grants $900,000 toward gene editing innovation

Joseph FraiettaPietro GenoveseSwim Across America, the nonprofit funding innovative clinical trials and patient-centered programs for cancer, awarded $450,000 grants to two of its beneficiaries, Alliance for Cancer Gene Therapy and Dana-Farber Cancer Institute, to support the work of novel gene and base editing techniques used in advanced cancer research, including targeted therapies, immunotherapies, and cellular therapies.

April 25, 2025

Vol.51 No.16

Clinical Roundup

Heated intraperitoneal chemotherapy associated with longer survival in ovarian cancer

Physicians at Tampa General Hospital and USF Health Morsani College of Medicine conducted a multicenter, retrospective cohort study and found that a highly specialized treatment—heated intraperitoneal chemotherapy delivered directly into the abdominal cavity, is associated with longer survival for women with metastatic epithelial ovarian cancer.

April 18, 2025

Vol.51 No.15

Clinical Roundup

Phase II trial analysis shows higher ORR in HR MDS when treated with bexmarilimab + azacitidine

Faron Pharmaceuticals Ltd. on April 14 announced positive topline results of the BEXMAB trial, which shows a high overall response rate among both frontline as well as relapsed/refractory high-risk myelodysplastic syndromes patients treated with a combination of bexmarilimab and azacitidine.

April 18, 2025

Vol.51 No.15

Research finds ECOG scores restrict patient access to trials, preventing trials from accurately representing real-world patients

YOU MAY BE INTERESTED IN

HHS said it would terminate Women’s Health Initiative, then reconsidered

NIH notice prohibits grant awardees from operating programs that promote DEI

Federal judges rule that Department of Education policy ordering universities to end DEI programs a violation of educators’ free speech

Swim Across America grants $900,000 toward gene editing innovation

Heated intraperitoneal chemotherapy associated with longer survival in ovarian cancer

Phase II trial analysis shows higher ORR in HR MDS when treated with bexmarilimab + azacitidine

Renew today!

Subscriber content

Never miss an issue!

Login